ESMO 2019 Testicular Cancer

Viewing 1-7 of 7 articles

ESMO 2019: Invited Discussant: Testicular and Kidney Cancer (913PD - APACHE (Testicular), 914PD (Testicular) , and 915PD (RCC))

ESMO 2019: Prognostic Factors in Metastatic Seminomatous Germ Cell Tumors and Elevated HCG – a Study of the G3

ESMO 2019: APACHE: An Open Label, Randomized, Phase II Study of Durvalumab Alone or in Combination with Tremelimumab, in Patients with Refractory Germ Cell Tumors: Results from the Expanded Combination Therapy Cohort

ESMO 2019: Prognostic Factors in Metastatic Seminomatous Germ Cell Tumors and Elevated Human Chorionic Gonadotrophin – Study of the G3

ESMO 2019: APACHE: An Open Label, Randomized, Phase 2 Study of Durvalumab, Alone or in Combination with Tremelimumab, in Patients with Refractory Germ Cell Tumors: Results from the Expanded Combination Therapy Cohort

ESMO 2019: Invited Discussant - Redefining the International Germ Cell Cancer Collaborative Group Classification in Advanced Non-Seminoma

ESMO 2019: The International Germ Cell Cancer Collaborative Group Classification in Advanced Non-Seminoma - Redefined